Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland.
Department of Clinical Oncology, Oncology Center in Opole, Opole, Poland.
J Immunol Res. 2017;2017:4861570. doi: 10.1155/2017/4861570. Epub 2017 Oct 3.
Prostate cancer treatment is currently based on surgical removal, radiotherapy, and hormone therapy. In recent years, another therapeutic method has emerged-immunological treatment. Immunotherapy modulates and strengthens one's immune responses against cancer. Neoplastic cells naturally escape from the control of the immune system, and the main goal of immune therapy is to bring the control back. Satisfying outcomes after treatment of advanced melanoma and lung cancer suggest a great potential of immunotherapy as an approach for other tumors' treatment, especially in patients primarily introduced to palliative care. After initial clinical trials, immunotherapy seems to have different side effects than chemotherapy. Prostate cancer was the first neoplasm in which a specific vaccine significantly improved survival. There is a tremendous potential for synergistic combinations of immunotherapy with conventional cancer treatments. A combination of several drugs or methods can be a key in radical treatment of metastatic prostate cancer as demonstrated by preliminary studies.
前列腺癌的治疗目前基于手术切除、放疗和激素治疗。近年来，另一种治疗方法出现了——免疫治疗。免疫疗法调节和增强了人体对癌症的免疫反应。肿瘤细胞自然逃脱免疫系统的控制，免疫治疗的主要目标是重新获得控制。晚期黑色素瘤和肺癌治疗后的满意结果表明，免疫疗法作为治疗其他肿瘤的一种方法具有巨大的潜力，特别是在最初引入姑息治疗的患者中。经过初步临床试验，免疫疗法的副作用似乎与化疗不同。前列腺癌是第一种特定疫苗显著改善生存的肿瘤。免疫疗法与传统癌症治疗的协同组合具有巨大的潜力。初步研究表明，几种药物或方法的联合可能是根治转移性前列腺癌的关键。
